Animal Models Evaluating Platelet-Modifying Drugs

  • L. A. Harker

Abstract

Acute thrombotic and thromboembolic occlusion of atherosclerotic vessels causes most heart attacks and strokes, and these acute events comprise respectively the first and third leading causes of mortality in the Western world. Thus, the development and testing of effective antithrombotic therapies are important public health strategies. Our understanding of the basic molecular processes involved in the formation and dissolution of thrombus in vitro has expanded rapidly in recent years, and this basic research has led to the development of new and potentially important antithrombotic agents. The evaluation of these new antithrombotic agents requires appropriate and relevant animal models of acute thrombosis. Indeed, the myriad of new antithrombotic pharmacologic agents being developed by peptide synthesis and recombinant DNA technology will be increasingly dependent on testing in vivo to assure their efficacy, safety, and timely application [1]. However, many animal models of thrombosis and thromboembolization have had limited usefulness in the past, particularly where the assessment of vascular occlusion has involved experimental animal species of questionable relevance to man and observations at a single point in time following an initiating vascular insult [2,3]. Additionally, uncontrolled variables may compromise the quantitative aspects of such models. Such uncontrolled factors include the type and extent of the initial vascular injury, loss of thrombus by embolization, loss of thrombus by thrombolysis, hemodynamic characteristics of the model, and the timing and type of observations at death.

Keywords

Aspirin Heparin Serotonin Assure Ketone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cohen C (1986) The case for the use of animals in biomedical research. N Engl J Med 315:865–870PubMedCrossRefGoogle Scholar
  2. 2.
    Didisheim P (1972) Animal models useful in the study of thrombosis and antithrombotic agents. Prog Hemost Thromb 1:165–197PubMedGoogle Scholar
  3. 3.
    Migaki G, Casey HW (1976) Animal models of thrombosis and hemorrhagic diseases. Department of Health Education and Welfare, Public Health Service, National Institute of Health, Bethesda, pp 55–65 (NIH publno 76–982)Google Scholar
  4. 4.
    Hampton JW, Matthews C (1966) Similarities between baboon and human blood clotting. J Appl Physiol 21:1713–1716PubMedGoogle Scholar
  5. 5.
    Todd ME, McDevitt EL, Goldsmith EI (1972) Blood-clotting mechanisms of nonhuman primates: choice of the baboon model to simulate man. J Med Primatol 1:132–141PubMedGoogle Scholar
  6. 6.
    Harker LA, Hanson SR (1979) Experimental arterial thromboembolism in baboons: mechanism, quantitation and pharmacologic prevention. J Clin Invest 64:559–569PubMedCrossRefGoogle Scholar
  7. 7.
    Hanson SR, Harker LA, Ratner BD, Hoffman AS (1980) In vivo evaluation of artificial surfaces with a nonhuman primate model of arterial thrombosis. J Lab Clin Med 95:289–304PubMedGoogle Scholar
  8. 8.
    Hanson SR, Reidy MA, Hattori A, Harker LA (1982) Pharmacologic modification of acute vascular graft thrombosis. Scanning Electron Microsc 11:773–779Google Scholar
  9. 9.
    Hanson SR, Harker LA (1983) Effect of Dazoxiben on arterial graft thrombosis in the baboon. Br J Clin Pharmacol 15:57S–60SPubMedCrossRefGoogle Scholar
  10. 10.
    Hanson SR, Harker LA, Bjornsson TD (1985) Effects of platelet-modifying drugs on arterial thromboembolism in baboons. J Clin Invest 75:1591–1599PubMedCrossRefGoogle Scholar
  11. 11.
    Hanson SR, Harker LA (1985) Studies of suloctidil in experimental thrombosis in baboons. Thromb Haemost 53:423–427PubMedGoogle Scholar
  12. 12.
    Malpass TW, Hanson SR, Savage B, Hessel EA II, Harker LA (1981) Prevention of acquired transient defect in platelet plug formation by infused prostacyclin. Blood 57:736–740PubMedGoogle Scholar
  13. 13.
    Hanson SR, Kotze HF, Savage B, Harker LA (1985) Platelet interactions with Dacron vascular grafts. Arteriosclerosis 5:595–603PubMedCrossRefGoogle Scholar
  14. 14.
    Callow AD, Ledig CB, O’Donnell TF et al. (1980) A primate model for the study of the interaction of 111In-labeled baboon platelets with Dacron arterial prostheses. Ann Surg 191:362–366PubMedCrossRefGoogle Scholar
  15. 15.
    Clowes AW, Gown AM, Hanson SR, Reidy MA (1985) Mechanisms of arterial graft failure: role of cellular proliferation in early healing of PTFE prostheses. AM J Pathol 118:43–54PubMedGoogle Scholar
  16. 16.
    Reidy MA, Chao SS, Kirkman TR, Clowes AW (1986) Endothelial regeneration: chronic nondenuding injury in baboon vascular grafts. Am J Pathol 123:432–439PubMedGoogle Scholar
  17. 17.
    Clowes AW, Kirkman TR, Reidy MA (1986) Mechanisms of arterial graft healing: rapid transmural capillary ingrowth provides a source of intimal endothelium and smooth muscle in porous PTFE prostheses. Am J Pathol 123:220–230PubMedGoogle Scholar
  18. 18.
    Savage B, Hanson SR, Harker LA (1986) The relation of platelet density to platelet age: survival of low and high density ‘Indium-labeled platelets in baboons. Blood 68:386–393PubMedGoogle Scholar
  19. 19.
    Harker LA, Ross R, Slichter S, Scott C (1976) Homocystine-induced arteriosclerosis The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 58:731–741PubMedCrossRefGoogle Scholar
  20. 20.
    Taylor FB Jr, Chang A, Esmon CT, D’Angelo A, Vigano-D’Angelo S, Blick KE (1987) Protein C prevents the coagulopathic and lethal effects of escherichia coli infusion in the baboon. J Clin Invest 79:918–925PubMedCrossRefGoogle Scholar
  21. 21.
    Hanson SR, Harker LA (1987) Baboon models of acute arterial thrombosis. Thromb Haemost 58:801–805PubMedGoogle Scholar
  22. 22.
    Hanson SR, Pareti FI, Ruggeri ZM et al. (1988) Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon. JClin Invest 81:149–158CrossRefGoogle Scholar
  23. 23.
    Hanson SR, Harker LA (1988) Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-Larginyl chloromethyl ketone. Proc Natl Acad Sci USA 85:3184–3188PubMedCrossRefGoogle Scholar
  24. 24.
    Gruber A, Griffin JH, Harker LA, Hanson SR (1989) Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model. Blood 73:639–642PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • L. A. Harker

There are no affiliations available

Personalised recommendations